» Articles » PMID: 20473378

Fenofibrate Reduces Age-related Hypercholesterolemia in Normal Rats on a Standard Diet

Overview
Specialty Pharmacology
Date 2010 May 18
PMID 20473378
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Plasma cholesterol is increased in normal aging in both rodents and humans. This is associated with reduced elimination of cholesterol and decreased receptor-mediated clearance of plasma low-density lipoprotein (LDL) cholesterol. The aims of this study were: (1) to determine age-related changes in plasma lipid profiles, and (2) to determine the effect of fenofibrate, an activator of peroxisome proliferator activated receptor alpha (PPAR alpha), on plasma lipid profiles in normal rats on a standard diet. Male Sprague-Dawley (SD) rats (n=15) were fed standard chow and water from 10 to 25 weeks of age. During that period, we measured daily food intake, body weight, fasting and random blood glucose levels, plasma total cholesterol (TC), triglycerides (TG), and free fatty acid (FFA) levels. At 20 weeks of age, all rats were randomly divided into two groups: a fenofibrate group (in which rats were gavaged with 300 mg/kg/day of fenofibrate) and a control group (gavaged with water). Fenofibrate treatment lasted 5 weeks. There were no significant changes in daily food intake, blood glucose, and plasma TG level with age. Body weight, plasma TC, and FFA levels were significantly increased with age. Fenofibrate significantly decreased plasma concentrations of TC and FFA, which had been increased with age. However, fenofibrate did not influence the plasma concentration of TG, which had not increased with age. These results suggest that fenofibrate might have a novel role in preventing age-related hypercholesterolemia in SD rats on a normal diet.

Citing Articles

Ovariectomy Impaired Hepatic Glucose and Lipid Homeostasis and Altered the Gut Microbiota in Mice With Different Diets.

Lei Z, Wu H, Yang Y, Hu Q, Lei Y, Liu W Front Endocrinol (Lausanne). 2021; 12:708838.

PMID: 34276568 PMC: 8278766. DOI: 10.3389/fendo.2021.708838.


Reduction of Food Intake by Fenofibrate is Associated with Cholecystokinin Release in Long-Evans Tokushima Rats.

Park M, Han Y, Kim M, Seo E, Kang S, Park S Korean J Physiol Pharmacol. 2012; 16(3):181-6.

PMID: 22802699 PMC: 3394920. DOI: 10.4196/kjpp.2012.16.3.181.


Kidney aging--inevitable or preventable?.

Choudhury D, Levi M Nat Rev Nephrol. 2011; 7(12):706-17.

PMID: 21826079 DOI: 10.1038/nrneph.2011.104.

References
1.
Kobayashi A, Suzuki Y, Kuno H, Sugai S, Sakakibara H, Shimoi K . Effects of fenofibrate on plasma and hepatic transaminase activities and hepatic transaminase gene expression in rats. J Toxicol Sci. 2009; 34(4):377-87. DOI: 10.2131/jts.34.377. View

2.
Trapani L, Violo F, Pallottini V . Hypercholesterolemia and 3-hydroxy-3-methylglutaryl coenzyme A reductase regulation in aged female rats. Exp Gerontol. 2009; 45(2):119-28. DOI: 10.1016/j.exger.2009.10.014. View

3.
Grundy S, Cleeman J, Rifkind B, Kuller L . Cholesterol lowering in the elderly population. Coordinating Committee of the National Cholesterol Education Program. Arch Intern Med. 1999; 159(15):1670-8. DOI: 10.1001/archinte.159.15.1670. View

4.
Levine G, Keaney Jr J, Vita J . Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms. N Engl J Med. 1995; 332(8):512-21. DOI: 10.1056/NEJM199502233320807. View

5.
Willson T, Wahli W . Peroxisome proliferator-activated receptor agonists. Curr Opin Chem Biol. 1997; 1(2):235-41. DOI: 10.1016/s1367-5931(97)80015-4. View